![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DPY19L3 |
Gene summary for DPY19L3 |
![]() |
Gene information | Species | Human | Gene symbol | DPY19L3 | Gene ID | 147991 |
Gene name | dpy-19 like C-mannosyltransferase 3 | |
Gene Alias | DPY19L3 | |
Cytomap | 19q13.11 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q6ZPD9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
147991 | DPY19L3 | male-WTA | Human | Thyroid | PTC | 4.38e-17 | 1.66e-01 | 0.1037 |
147991 | DPY19L3 | PTC01 | Human | Thyroid | PTC | 5.71e-04 | 2.29e-02 | 0.1899 |
147991 | DPY19L3 | PTC04 | Human | Thyroid | PTC | 1.79e-25 | 1.45e-01 | 0.1927 |
147991 | DPY19L3 | PTC05 | Human | Thyroid | PTC | 4.82e-09 | 2.69e-01 | 0.2065 |
147991 | DPY19L3 | PTC06 | Human | Thyroid | PTC | 5.61e-10 | 2.58e-01 | 0.2057 |
147991 | DPY19L3 | PTC07 | Human | Thyroid | PTC | 1.71e-17 | 2.02e-01 | 0.2044 |
147991 | DPY19L3 | ATC12 | Human | Thyroid | ATC | 8.95e-11 | 4.92e-02 | 0.34 |
147991 | DPY19L3 | ATC13 | Human | Thyroid | ATC | 5.34e-32 | 5.11e-01 | 0.34 |
147991 | DPY19L3 | ATC2 | Human | Thyroid | ATC | 1.39e-03 | 7.81e-01 | 0.34 |
147991 | DPY19L3 | ATC4 | Human | Thyroid | ATC | 5.54e-09 | 1.02e-01 | 0.34 |
147991 | DPY19L3 | ATC5 | Human | Thyroid | ATC | 2.33e-27 | 5.54e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00064866 | Thyroid | PTC | protein glycosylation | 94/5968 | 226/18723 | 1.25e-03 | 7.13e-03 | 94 |
GO:00434136 | Thyroid | PTC | macromolecule glycosylation | 94/5968 | 226/18723 | 1.25e-03 | 7.13e-03 | 94 |
GO:00700855 | Thyroid | PTC | glycosylation | 96/5968 | 240/18723 | 4.57e-03 | 2.15e-02 | 96 |
GO:00091013 | Thyroid | PTC | glycoprotein biosynthetic process | 123/5968 | 317/18723 | 5.05e-03 | 2.33e-02 | 123 |
GO:00091003 | Thyroid | PTC | glycoprotein metabolic process | 147/5968 | 387/18723 | 5.87e-03 | 2.64e-02 | 147 |
GO:000648612 | Thyroid | ATC | protein glycosylation | 94/6293 | 226/18723 | 7.11e-03 | 2.82e-02 | 94 |
GO:004341312 | Thyroid | ATC | macromolecule glycosylation | 94/6293 | 226/18723 | 7.11e-03 | 2.82e-02 | 94 |
GO:000910011 | Thyroid | ATC | glycoprotein metabolic process | 153/6293 | 387/18723 | 7.90e-03 | 3.06e-02 | 153 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DPY19L3 | SNV | Missense_Mutation | c.1814N>A | p.Arg605Lys | p.R605K | Q6ZPD9 | protein_coding | tolerated(0.59) | probably_damaging(0.996) | TCGA-A7-A13F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
DPY19L3 | SNV | Missense_Mutation | novel | c.502N>A | p.Ala168Thr | p.A168T | Q6ZPD9 | protein_coding | tolerated(0.17) | benign(0.038) | TCGA-BH-A0BW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | CR |
DPY19L3 | SNV | Missense_Mutation | rs766109273 | c.1256A>G | p.Tyr419Cys | p.Y419C | Q6ZPD9 | protein_coding | tolerated(0.17) | possibly_damaging(0.905) | TCGA-BH-A0GY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyotxan | SD |
DPY19L3 | SNV | Missense_Mutation | novel | c.755N>C | p.Phe252Ser | p.F252S | Q6ZPD9 | protein_coding | deleterious(0.02) | benign(0.156) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DPY19L3 | SNV | Missense_Mutation | novel | c.1861N>A | p.Glu621Lys | p.E621K | Q6ZPD9 | protein_coding | tolerated(0.05) | possibly_damaging(0.794) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
DPY19L3 | SNV | Missense_Mutation | novel | c.1460G>C | p.Trp487Ser | p.W487S | Q6ZPD9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A43B-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DPY19L3 | SNV | Missense_Mutation | c.2045N>A | p.Arg682His | p.R682H | Q6ZPD9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EK-A2R8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
DPY19L3 | SNV | Missense_Mutation | c.1195G>C | p.Glu399Gln | p.E399Q | Q6ZPD9 | protein_coding | deleterious(0) | probably_damaging(0.918) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
DPY19L3 | SNV | Missense_Mutation | c.1992N>A | p.Met664Ile | p.M664I | Q6ZPD9 | protein_coding | tolerated(0.62) | benign(0) | TCGA-AA-3842-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folinic | PD | |
DPY19L3 | SNV | Missense_Mutation | c.356A>C | p.Lys119Thr | p.K119T | Q6ZPD9 | protein_coding | tolerated(0.16) | benign(0.077) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |